Copyright
©The Author(s) 2024.
World J Psychiatry. Apr 19, 2024; 14(4): 523-532
Published online Apr 19, 2024. doi: 10.5498/wjp.v14.i4.523
Published online Apr 19, 2024. doi: 10.5498/wjp.v14.i4.523
Table 1 Characteristics of sociodemographic and clinical variables
Characteristic (n = 50) | Minimum value | Maximum value | Mean value | SD |
Age (yr) | 38 | 69 | 58.38 | 8.31 |
BMI | 16.02 | 36.05 | 23.95 | 4.82 |
Course of illness (yr) | 15 | 51 | 33.32 | 9.18 |
Systolic blood pressure (mmHg) | 90 | 180 | 130.08 | 18.21 |
Diastolic blood pressure (mmHg) | 60 | 105 | 78.60 | 10.32 |
Heart rate (per min) | 60 | 103 | 79.86 | 9.79 |
QTc | 0.38 | 0.52 | 0.45 | 0.03 |
Mean PANSS positive subscale score | 7 | 20 | 10.92 | 3.17 |
Mean PANSS negative subscale score | 9 | 31 | 22.32 | 4.20 |
Mean PANSS general psychopathology subscale score | 22 | 51 | 31.04 | 5.07 |
Mean PANSS total score | 48 | 101 | 64.28 | 8.89 |
PHQ-9 | 0 | 9 | 1.82 | 1.64 |
Table 2 Risperidone dose and plasma concentrations of risperidone and 9 hydroxyrisperidone according to sex
Sex | n | Average | SD | P value | |
Risperidone dose (mg)1 | Male | 32 | 4.09 | 1.12 | 0.003 |
Female | 18 | 3.11 | 0.90 | ||
Total | 50 | 3.74 | 1.14 | ||
Risperidone dose per kg weight2 | Male | 32 | 0.06 | 0.02 | 0.010 |
Female | 18 | 0.05 | 0.02 | ||
Total | 50 | 0.06 | 0.02 | ||
Concentration of risperidone in plasma (ng/mL)1 | Male | 32 | 8.61 | 10.80 | 0.134 |
Female | 18 | 15.13 | 15.27 | ||
Total | 50 | 10.96 | 12.83 | ||
Concentration of 9-hydroxyrisperidone in plasma (ng/mL)1 | Male | 32 | 32.37 | 18.63 | 0.887 |
Female | 18 | 29.24 | 10.25 | ||
Total | 50 | 31.24 | 16.07 | ||
Concentration of risperidone + 9-hydroxyrisperidone in plasma (ng/mL)1 | Male | 32 | 40.98 | 23.98 | 0.293 |
Female | 18 | 44.37 | 18.79 | ||
Total | 50 | 42.20 | 22.11 | ||
Concentration of risperidone + 9-hydroxyrisperidone in plasma/dose2 | Male | 32 | 9.87 | 4.18 | 0.010 |
Female | 18 | 14.89 | 6.96 | ||
Total | 50 | 11.68 | 5.81 | ||
Concentration of risperidone + 9-hydroxyrisperidone in plasma/(dose × kg)1 | Male | 32 | 0.16 | 0.07 | 0.017 |
Female | 18 | 0.24 | 0.12 | ||
Total | 50 | 0.18 | 0.10 |
Table 3 Correlation of average concentrations of risperidon + 9-hydroxyrisperidone in plasma/(dose × kg) according to sex with clinical and psychopathological variables
Correlation of average concentration in plasma/(dose × kg) with | Correlation coefficient | P value |
Male (n = 32) | ||
Age (yr) | 0.4572 | 0.008 |
Number of cigarettes (smokers) | -0.3591 | 0.092 |
Systolic blood pressure | 0.0962 | 0.600 |
Diastolic blood pressure | 0.1262 | 0.492 |
BMI | -0.2711 | 0.134 |
Heart rate | -0.1731 | 0.344 |
QTc | 0.0602 | 0.743 |
Mean PANSS positive scale score | 0.1792 | 0.328 |
Mean PANSS negative scale score | 0.3731 | 0.035 |
Mean PANSS general psychopathology subscale score | 0.3891 | 0.028 |
Mean PANSS total score | 0.4812 | 0.005 |
Female (n = 18) | ||
Age | 0.4361 | 0.071 |
Systolic blood pressure | -0.1732 | 0.492 |
Diastolic blood pressure | 0.0242 | 0.925 |
BMI | -0.4462 | 0.064 |
Heart rate | 0.1322 | 0.600 |
QTc | 0.0592 | 0.816 |
Mean PANSS positive subscale score | -0.2541 | 0.310 |
Mean PANSS negative subscale score | -0.1302 | 0.607 |
Mean PANSS general psychopathology subscale score | 0.3752 | 0.125 |
Mean PANSS total score | 0.0642 | 0.801 |
Table 4 Comparison between adverse drug reaction groups and non-adverse drug reaction group
Trihexyphenidyl group (n = 10) | No trihexyphenidyl group (n = 40) | P/Z value | |
Risperidone dose per kg weight2 | 0.07 ± 0.03 | 0.06 ± 0.02 | 0.129 |
Concentration of risperidone in plasma (ng/mL)1 | 11.18 ± 11.98 | 10.90 ± 13.18 | 0.899 |
Concentration of 9-hydroxyrisperidone in plasma (ng/mL)2 | 42.94 ± 26.33 | 28.32 ± 10.98 | 0.117 |
Concentration of risperidon + 9-hydroxyrisperidone in plasma (ng/mL)2 | 54.12 ± 33.68 | 39.22 ± 17.52 | 0.205 |
Concentration of risperidon + 9-hydroxyrisperidone in plasma/dose1 | 11.77 ± 5.67 | 11.65 ± 5.92 | 0.923 |
Concentration of risperidon + 9-hydroxyrisperidone in plasma/(dose × kg)1 | 0.17 ± 0.08 | 0.19 ± 0.10 | 0.577 |
Laxative drug group (n = 10) | No laxative drug group (n = 40) | P/Z value | |
Risperidone dose per kg weight2 | 0.06 ± 0.02 | 0.06 ± 0.02 | 0.667 |
Concentration of risperidone in plasma (ng/mL)1 | 11.87 ± 14.22 | 10.71 ± 12.65 | 0.971 |
Concentration of 9-hydroxyrisperidone in plasma (ng/mL)1 | 37.77 ± 28.34 | 29.61 ± 11.20 | 0.914 |
Concentration of risperidon + 9-hydroxyrisperidone in plasma (ng/mL)1 | 49.64 ± 36.20 | 40.35 ± 17.15 | 0.877 |
Concentration of risperidon + 9-hydroxyrisperidone in plasma/dose1 | 12.81 ± 6.25 | 11.39 ± 5.75 | 0.465 |
Concentration of risperidon + 9-hydroxyrisperidone in plasma/(dose × kg)1 | 0.19 ± 0.07 | 0.18 ± 0.11 | 0.607 |
- Citation: Xu JW, Guan XB, Wang XY, Feng Y, Zhang Q, Zhu JJ, Chen JH. Relationship between plasma risperidone concentrations and clinical features in chronic schizophrenic patients in China. World J Psychiatry 2024; 14(4): 523-532
- URL: https://www.wjgnet.com/2220-3206/full/v14/i4/523.htm
- DOI: https://dx.doi.org/10.5498/wjp.v14.i4.523